Kovac M, et al. - Researchers analyzed data from ZOE-50 and ZOE-70 trials, wherein an adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and post-herpetic neuralgia (PHN) in adults ≥50 and ≥70 years of age. The goal herein was to assess the efficacy of HZ/su against complications of HZ, including non-PHN complications. Findings demonstrated that HZ/su reduced the risk of HZ-associated complications in older adults.